Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. The Organogenesis news feed highlights company announcements, clinical updates, financial results, and regulatory developments that help investors and healthcare professionals understand how the business is evolving.
News about Organogenesis frequently covers its regenerative medicine portfolio and its position in the skin substitutes and cellular and tissue-based products (CTP) market. The company issues press releases on quarterly and year-to-date financial performance, including net product revenue from Advanced Wound Care and Surgical & Sports Medicine products, net income or loss, and adjusted metrics such as adjusted net income and adjusted EBITDA. These updates often include management commentary on market conditions, reimbursement dynamics, and expectations for future periods.
A major theme in Organogenesis news is the development of ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis. The company publishes detailed updates on Phase 3 randomized controlled trials, including pain and function outcomes, safety observations, and plans for regulatory submissions. Announcements have described FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ReNu, plans for a Biologics License Application (BLA), and the initiation of a rolling BLA submission.
Additional news items include commentary on Centers for Medicare & Medicaid Services (CMS) payment reforms for skin substitutes/CTPs, participation in investor conferences, and corporate governance developments such as inducement equity grants and stockholder meeting results. By following this page, readers can review a chronological record of how Organogenesis communicates its financial performance, clinical progress, reimbursement environment, and corporate actions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced that it will report its third quarter fiscal year 2022 financial results on November 9, 2022, after market closure. A conference call will follow at 5:00 p.m. ET on the same day, offering a corporate update and a Q&A session. Interested participants can access the call via a live webcast or teleconference, with an archived version available on the company’s website for one year. Organogenesis focuses on regenerative medicine solutions for advanced wound care and surgical markets.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference, taking place from September 12-14, 2022, at the Sheraton New York Times Square Hotel. The management will engage in a fireside chat on September 13 at 11:45 a.m. Eastern Time. A live audio webcast of the presentation will be available on the company’s website, with a replay accessible for 30 days post-conference. Organogenesis specializes in regenerative medicine, focusing on advanced wound care and surgical solutions.
Organogenesis Receives FDA Clearance for PuraPly MZ
On August 15, 2022, Organogenesis announced the FDA clearance of PuraPly MZ, an innovative powdered product for complex surgical wounds. This marks a significant milestone as it expands their PuraPly portfolio into the surgical and sports medicine markets. PuraPly MZ utilizes native structured collagen to enhance healing in complex wounds, addressing a pressing need in the medical community, with estimates indicating that 28% of surgical sites in the U.S. require specific attention for effective healing.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q2 2022 net revenue of $121.4 million, down 1% year-over-year, with Advanced Wound Care up 2% to $113.8 million while Surgical & Sports Medicine fell 35% to $7.6 million. Net income decreased significantly by 58% to $8.7 million, or $0.07 per share. Adjusted EBITDA dropped to $18.6 million from $25.1 million a year ago. For FY 2022, the company projects revenue between $465 million and $490 million, reflecting a modest annual decline or growth.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced its second quarter fiscal year 2022 financial results will be released after market close on August 9, 2022. A conference call will follow at 5:00 p.m. Eastern Time, providing an overview of the results and corporate updates. Interested participants can access the live webcast through the company's investor relations website. The archived version will also be available for roughly one year. Organogenesis specializes in regenerative medicine, focusing on products for Advanced Wound Care and Surgical & Sports Medicine.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q1 2022 financial results with net revenue of $98.1 million, down 4% year-over-year. Revenue from Advanced Wound Care increased by 0.3% to $91.0 million, while Surgical & Sports Medicine revenue fell 39% to $7.2 million. Net income plummeted to $0.1 million from $9.9 million, a decrease of $9.9 million. Adjusted EBITDA also dropped 69% to $5.0 million. The company projects net revenue for 2022 to be between $485 million and $515 million, indicating an anticipated growth of 4% to 10%.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced the appointments of Michele Korfin and Gilberto Quintero, Ph.D. to its Board of Directors, effective May 3, 2022. Both directors bring extensive experience from various leadership roles in the healthcare industry. Korfin, with previous roles at Gamida Cell and Kite Pharma, holds an MBA from Harvard and has a strong background in market access and commercialization. Quintero has served as Chief Quality Officer at Kimberly-Clark and holds a Ph.D. in Chemistry. This move enhances the board's independence, with a majority now being independent directors.
Organogenesis announced its participation as a leading sponsor at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference in Phoenix, Arizona, from April 6-10, 2022. The company will present new research on its wound care products, including PuraPly® AM and Apligraf®. Key events include a breakfast symposium on randomized controlled trials and an Innovation Theatre lunch discussing chronic wound treatment. Attendees can visit booth #703 for insights into the latest advanced wound care solutions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will announce its first quarter fiscal 2022 financial results after market close on May 10th. Following the announcement, management will host a conference call at 5:00 p.m. ET to discuss the results and provide a corporate update, including a Q&A session. Participants can join by dialing 866-795-3142 or 409-937-8908 for international calls, using access code 3349739. A live webcast will also be available on the company's investor relations website, with an archive accessible for one year.
Summary not available.
FAQ
What is the current stock price of Organogenesis Hldgs (ORGO)?
What is the market cap of Organogenesis Hldgs (ORGO)?
